Vol. 5 No. 6 (2025)
Reimbursement Recommendations

Efanesoctocog Alfa (ALTUVIIIO)

decorative image of the issue cover

Published June 5, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that ALTUVIIIO should be reimbursed for the treatment of hemophilia A (congenital factor VIII [FVIII] deficiency) if certain conditions are met.
  • ALTUVIIIO should be covered to treat patients living with hemophilia A, provided it is covered for a patient population similar to that of other FVIII replacement therapies currently reimbursed for the treatment of patients with hemophilia A.
  • ALTUVIIIO should only be reimbursed in a similar way as other FVIII replacement therapies that are currently reimbursed for the treatment of patients with hemophilia A. The cost of ALTUVIIIO should be negotiated so that it does not exceed the annual drug program cost of treatment currently reimbursed for prophylactic use in hemophilia A.